Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)

HIV Infections Clinical Trial

— DAYANA  

Official title:

Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00573001
• Other study ID #: ANRS12115 DAYANA
• Secondary ID: IMEA 032
• Status: Completed
• Phase: Phase 3
• First received: December 12, 2007
• Last updated: May 14, 2012
• Start date: July 2008
• Est. completion date: December 2011

Study information

• Verified date: May 2012
• Source: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Cameroon: Ministry of Public HealthSenegal: Ministere de la sante
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks). These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir.

Description:

The efficacy of antiretroviral treatments in sub-Saharan Africa has been demonstrated in cohort studies and pilot trials. The treatment regimens tested in these studies were derived from those used in pre-marketing trials conducted in industrialized countries.

However, the choice of antiretrovirals for national programs in poor countries is largely based on drug availability through the Access program, together with cost and supply considerations, rather than on field evaluations of recommended strategies.

Concomitantly with the development of antiretroviral access programs in the southern hemisphere, first-line treatments in industrialized countries have tended to become simpler, thereby improving their convenience and reducing the incidence and severity of their adverse effects. These simplified treatments involve fewer tablets and intakes, fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor and tenofovir. These simplified strategies are being extensively evaluated in industrialized countries.

Long-term economic benefits will be a determining factor in the adoption of these strategies by poor countries.

Methods:

We will conduct a phase-III unblinded randomised trial focusing on the early virologic efficacy, tolerability and immuno-virologic efficacy of four simplified antiretroviral regimens given for 96 weeks to previously untreated HIV-1-infected patients in Senegal and Cameroon. The following four simplified treatments will be tested: TDF/FTC/NVP, LPV/TDF, TDF/FTC/AZT and TDF/FTC/EFV. The required number of patients (n=120) is compatible with the short-term recruitment capacity of two clinical investigation centers in Senegal and Cameroon.

Objective:

The goal of this trial is to demonstrate that these new treatments are as effective as a reference triple-agent regimen (TDF/FTC/EFV) in driving plasma viral load below the detection limit early during treatment. The principal objective is to identify simplified treatments capable of driving viral load below 50 copies/mL at week 16 in at least 50% of patients. If successful, the initial treatments will be continued and re-assessed at 96 weeks.

Study design:

120 patients previously unexposed to antiretroviral drugs will be recruited over a one-year period in two treatment centers in Dakar (Infectious Diseases department of Fann University Hospital) and Cameroon (Yaounde Military Hospital and Principal Hospital)

Expected results:

This study is fully in keeping with WHO/UNAIDS recommendations on antiretroviral treatment simplification in poor countries. These new treatments must be evaluated in the countries concerned, given the often very advanced stage of HIV disease at diagnosis, intercurrent health disorders, and local socioeconomic conditions.

This trial is not designed to compare these new treatments with one another, but rather to select the most promising treatments for future use. These preliminary results will help with the choice of treatment strategies for cohort studies and large-scale randomized trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: December 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age over 18 years for Senegal and over 21 years for Cameroon

• HIV-1 infected patient

• patient naive from any antiretroviral treatment

• CD4 cell count over 50 cells per mm3

• contraceptive method use

• informed consent signed

Exclusion Criteria:

• opportunistic infection ongoing or any other serious pathology

• ongoing treatment with rifampicine

• severe renal or hepatic impairment

• HbSAg positive

• Hemoglobine under 8g/L

• Neutrophils under 500 cells per mm3

• ongoing pregnancy or breastfeeding

• treatment by contra-indicated drugs (as described in study drugs notices)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Tenofovir/Emtricitabine (Truvada) and Nevirapine
Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
• Tenofovir/Emtricitabine/Efavirenz (Atripla)
Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
• Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
• Tenofovir/Emtricitabine (Truvada) and Zidovudine
Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day

Locations

Country	Name	City	State
Cameroon	Hopital Central	Yaounde
Senegal	Hopital de Fann	Dakar

Sponsors (4)

Lead Sponsor	Collaborator
French National Agency for Research on AIDS and Viral Hepatitis	Gilead Sciences, Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba, Merck Sharp & Dohme Corp.

Countries where clinical trial is conducted

Cameroon,  Senegal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with viral load below 50 copies/mL		week 16	No
Secondary	Percentage of patients with viral Load under 50 copies/ml and under 400 copies/ml		W4, W12, W24, W36, W72, and W96	No
Secondary	Severe adverse event onset, metabolic alterations, lipodystrophia		J0, W16, W24, W48, W72, W96	Yes
Secondary	Residual ARV plasmatic concentration		W4, W48	No
Secondary	CD4 count evolution		J0, W4, W16, W24, W36, W48, W72, W96	No
Secondary	quality of life parameters, observance		J0, W4, W8, W12, W16, W24, W36, W48, W72, W96	No

External Links

•   Sponsor web page